about
Biological predictors of pharmacological therapy in anxiety disordersBiological markers for anxiety disorders, OCD and PTSD - a consensus statement. Part I: Neuroimaging and genetics.Association of limbic system-associated membrane protein (LSAMP) to male completed suicide.Polymorphisms in the interleukin-10 gene cluster are possibly involved in the increased risk for major depressive disorder.Human microRNAs miR-22, miR-138-2, miR-148a, and miR-488 are associated with panic disorder and regulate several anxiety candidate genes and related pathways.Polymorphisms of IKBKE gene are associated with major depressive disorder and panic disorderSerotonin function in panic disorder: important, but why?Subjective Well-Being Under Neuroleptics Scale short form (SWN-K): reliability and validity in an Estonian speaking sampleThe role of IL-2 and soluble IL-2R in depression and antidepressant response.Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.Neuroimaging of serotonin system in anxiety disorders.Genetic factors in anxiety disorders.The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.Effect of short-term escitalopram treatment on neural activation during emotional processing.Biological markers of generalized anxiety disorder.Thyroid autoimmunity and treatment response to escitalopram in major depression.Citalopram challenge in social anxiety disorder.The effect of 5-hydroxytryptophan on cholecystokinin-4-induced panic attacks in healthy volunteers.Association between serotonin-related genetic polymorphisms and CCK-4-induced panic attacks with or without 5-hydroxytryptophan pretreatment in healthy volunteers.SPECT imaging of serotonin transporter binding in patients with generalized anxiety disorder.Reduced brain serotonin transporter binding in patients with panic disorder.Associations between serotonin-related gene polymorphisms and panic disorder.Association study of 90 candidate gene polymorphisms in panic disorder.Dopamine transporter binding in females with panic disorder may vary with clinical status.Variation in tryptophan hydroxylase-2 gene is not associated to male completed suicide in Estonian population.Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression.Common variations in 4p locus are related to male completed suicide.Peripheral gene expression profiling of CCK-4-induced panic in healthy subjects.Association testing of panic disorder candidate genes using CCK-4 challenge in healthy volunteers.Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder.Manifesto for a European anxiety disorders research network.Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression.The course of cognitive functioning after first-episode of psychosis: A six month follow-up study.A pilot study of the effect of short-term escitalopram treatment on brain metabolites and gamma-oscillations in healthy subjects.Whole-genome expression analysis reveals genes associated with treatment response to escitalopram in major depression.Association study of tryptophan hydroxylase 2 gene polymorphisms in panic disorder.Association between personality traits and Escitalopram treatment efficacy in panic disorder.Tryptophan depletion does not modify response to CCK-4 challenge in patients with panic disorder after treatment with citalopram.Unedited in vivo detection and quantification of γ-aminobutyric acid in the occipital cortex using short-TE MRS at 3 T.Evaluation of personality traits in panic disorder using Swedish universities Scales of Personality.
P50
Q26781100-D3061802-043D-4FA6-99B7-3529B25C1C28Q31114020-2A9B733D-F9C0-4650-A332-46FC6017F39DQ33330477-C4EA3E4C-D592-4041-B791-C32084A13E83Q33393456-1900ACAB-6575-405F-A5A0-67147ED8E73AQ34155527-64D6B006-D092-49CD-AA76-11CB5FAF061CQ35169186-33FAE15A-5C9C-436C-A75C-D7EAFB11749BQ36244896-52B2508C-8152-4545-A0AA-681E95659D78Q37357277-9BD22670-E32A-467B-B2F4-1478C304CDEEQ37541908-996D8C01-EA46-4254-8C34-C9B2684DE9BCQ37686937-F03CF69C-9D76-4F72-90A3-9B9673D2B009Q38013248-54AE25E9-91FD-461C-AFAD-3F926434E897Q38250005-F602D5F3-F78C-4626-A559-5EFF55E53E56Q39560010-6AA5D782-F197-4640-B4B7-A0DF2E931FE6Q40234397-2B92918C-8777-458D-9988-824CC9C43964Q41535712-FD441A94-83B4-4E1A-9BCB-2E28F8E9E46BQ43188680-D2324848-DEF1-4174-8819-C4A95B364FE7Q44740431-FDF69E0D-0325-4C40-8439-E5B99523C396Q44983985-6E7F53AA-6F5F-4A83-824B-268EA2E586A1Q45043258-86693886-F0C0-432A-A89A-7338BE6E5236Q45147407-BBD4AC03-DCD4-4ACA-B30C-A2CD42711FE7Q45186850-C95138B7-66D8-4D86-B4D0-AAFEA38A321BQ45238006-E4DC0923-C0BB-437E-A396-F7A0D22D4612Q45276127-76D847E7-CB07-42B7-B947-0AB2856DDBD9Q45997742-568902DF-109B-4884-83FB-C871A89C4F86Q46056271-9EFFD064-E153-4F26-BEC2-2AFD87444320Q46094498-CDB80789-ED95-4C53-8BB9-AC0560DE9AE1Q46179912-C4972650-7324-49AA-BED0-57E2D0A3DA86Q46217941-F4904DB0-4403-4306-B189-F9085D3E74EEQ46334440-459CE86C-79EA-451F-BD83-B831A6F6A2CDQ46919296-FF190D44-EF1A-4A0F-A39E-EC74ECCB5F47Q47398843-2ADF869D-1972-44F2-8213-B813CC5FCC36Q47830777-B6F8517E-BCC4-4AB7-A0F5-E647DDDCFBCEQ47913671-EA40E3F2-D072-4FA1-8C94-BC07262DDAD5Q48026468-A944684B-BFCB-4870-BE7F-FCB7B3DE7A75Q48047286-98ED94E3-F091-4E18-A1AC-745EA93BFF0BQ48360056-56F7A4E4-AD1F-4EFD-845D-48165AB8743BQ48607318-91FF4ACC-7528-49E2-984E-03BC7C963629Q48616543-DD13D33F-2B21-444C-979B-E629D2E402DAQ50708449-C472B3B2-F6EE-4BE1-B8A8-BAEBB10E34DFQ50722490-878404D5-BC22-489E-931C-F5871D91B6EC
P50
name
Eduard Maron
@ast
Eduard Maron
@en
Eduard Maron
@es
Eduard Maron
@nl
type
label
Eduard Maron
@ast
Eduard Maron
@en
Eduard Maron
@es
Eduard Maron
@nl
prefLabel
Eduard Maron
@ast
Eduard Maron
@en
Eduard Maron
@es
Eduard Maron
@nl
P214
P244
P21
P214
P244
no2007078438
P2953
Eduard_Maron
P31
P569
1975-11-14T00:00:00Z
P734
P735
P7859
lccn-no2007078438